Please login to the form below

Not currently logged in
Email:
Password:

IRX Therapeutics appoints Luba Greenwood to its board

She recently served as venture partner at Colt Ventures

Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.

Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.

Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.

“She has excelled as an investor, business development professional, lawyer and corporate strategist.”

Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.

Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.

Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”

6th December 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics